Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director David Malek acquired 4,166 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. Braveheart Bio Price PerformanceNASDAQ:BRVE traded up $0.20 during mid-day trading on Friday, reaching $30.00. Braveheart Bio, Inc. has a 12-month low of $28.47 and a 12-month high of $32.00. Get Braveheart Bio alerts:About Braveheart Bio(Get Free Report)Featured ArticlesWe are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.